Breaking News: Cellectis Successfully Completes Global Offering and Underwriters Exercise Option to Purchase Additional Shares
Breaking News: Cellectis Successfully Completes Global Offering and Underwriters Exercise Option to Purchase Additional Shares Description: NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today: the…